West Pharmaceutical Services (WST) Stock Looks Rich Against Its Cash Flow

West Pharmaceutical Services has logged a sharp share price climb so far in 2026, which puts fresh attention on what investors are really paying for in terms of its cash flows. With the stock now at US$412.62, the key issue is how that market price lines up against the money the business is expected to generate over time.

• The share price is up 49.3% year to date, which raises the question of whether recent enthusiasm has moved ahead of what the cash flows can support.
• Recent company updates highlight strong demand in key product lines and firmer profitability, which can influence how much cash West Pharmaceutical Services may be able to return to shareholders or reinvest.
• What if you looked at West Pharmaceutical Services through its earnings instead? See what West Pharmaceutical Services's 45.0x P/E says about the price.

The issue now is whether West Pharmaceutical Services' current valuation is justified by its cash flows when viewed through an intrinsic value lens based on those cash streams.

You can apply the same cash flow question you are asking of West Pharmaceutical Services across a wider set of 36 high quality undervalued stocks

Does West Pharmaceutical Services Look Pricey on Cash Flow?

The Discounted Cash Flow (DCF) model here rests on what West Pharmaceutical Services can generate in free cash over time. Latest twelve month free cash flow sits at about $326.7 million, and the projections used in the model assume that this stream grows steadily into the early 2030s rather than swinging sharply higher or lower from year to year.

Those rising cash flow estimates are then discounted back and compared with today’s share price of US$412.62. On that basis the DCF outcome comes in meaningfully below where the stock trades. Because West Pharmaceutical Services recently reported strong Q3 2026 results and raised full year guidance, that upgraded outlook may help explain why investors currently value the shares above what these cash flow projections alone suggest. Find out what West Pharmaceutical Services could be worth using our Discounted Cash Flow (DCF) estimate.

The West Pharmaceutical Services Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the discounted cash flow puzzle for West Pharmaceutical Services' share price leaves off, by spelling out what would need to happen to future revenue, profitability and earnings for the stock to end up worth materially more or less than it is today. Instead of a single output from a ratio or model, Narratives show the future path that number assumes so you can watch how real world results stack up over time on the Community page.

One of the top community narratives on West Pharmaceutical Services: roughly fairly valued

"Bullish analysts point to West Pharmaceutical Services as a growth and margin expansion story, supported by continued strength in its high value products…"

Discover why this Narrative puts West Pharmaceutical Services at roughly fairly valued.

One more check for West Pharmaceutical Services sits with who steers it

Before you stop at the price tag and cash flows for West Pharmaceutical Services, it is worth asking who is steering the business and how their pay packets line up with your interests. See who runs West Pharmaceutical Services and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com